Stevens Capital Management LP bought a new stake in Inogen Inc (NASDAQ:INGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 5,507 shares of the medical technology company’s stock, valued at approximately $1,344,000.
Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Inogen by 7.2% in the second quarter. BlackRock Inc. now owns 2,591,083 shares of the medical technology company’s stock worth $482,796,000 after acquiring an additional 173,035 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Inogen by 43.3% during the 3rd quarter. Alliancebernstein L.P. now owns 373,794 shares of the medical technology company’s stock worth $91,251,000 after purchasing an additional 113,024 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Inogen by 19.9% during the 2nd quarter. Renaissance Technologies LLC now owns 309,814 shares of the medical technology company’s stock worth $57,728,000 after purchasing an additional 51,314 shares during the last quarter. OppenheimerFunds Inc. lifted its position in shares of Inogen by 40.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 286,147 shares of the medical technology company’s stock worth $53,318,000 after purchasing an additional 82,164 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Inogen by 3.9% during the 2nd quarter. Northern Trust Corp now owns 253,076 shares of the medical technology company’s stock worth $47,155,000 after purchasing an additional 9,425 shares during the last quarter. Hedge funds and other institutional investors own 98.65% of the company’s stock.
In related news, EVP Brenton Taylor sold 5,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $244.77, for a total value of $1,223,850.00. Following the completion of the sale, the executive vice president now directly owns 41,297 shares of the company’s stock, valued at $10,108,266.69. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Matt Scribner sold 2,000 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $281.23, for a total transaction of $562,460.00. Following the completion of the sale, the insider now directly owns 7,595 shares of the company’s stock, valued at $2,135,941.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,000 shares of company stock valued at $7,580,605. 5.29% of the stock is owned by corporate insiders.
Several equities research analysts have recently issued reports on INGN shares. BidaskClub raised shares of Inogen from a “strong sell” rating to a “sell” rating in a research report on Wednesday, November 28th. ValuEngine cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 1st. Needham & Company LLC cut shares of Inogen from a “strong-buy” rating to a “buy” rating and lifted their price objective for the stock from $254.00 to $296.00 in a research report on Monday, September 10th. Piper Jaffray Companies lifted their price objective on shares of Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 12th. Finally, Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $244.67.
Shares of INGN opened at $143.58 on Thursday. Inogen Inc has a 1-year low of $112.78 and a 1-year high of $287.79. The firm has a market capitalization of $3.07 billion, a P/E ratio of 109.60, a P/E/G ratio of 2.79 and a beta of 1.49.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.21. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The firm had revenue of $95.29 million during the quarter, compared to analysts’ expectations of $90.94 million. During the same period in the previous year, the company earned $0.33 earnings per share. Inogen’s quarterly revenue was up 38.0% compared to the same quarter last year. As a group, equities analysts predict that Inogen Inc will post 2.1 EPS for the current year.
WARNING: “Stevens Capital Management LP Takes Position in Inogen Inc (INGN)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/12/06/stevens-capital-management-lp-takes-position-in-inogen-inc-ingn.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Story: Intrinsic Value and Stock Selection
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.